Searchable abstracts of presentations at key conferences on calcified tissues
Volume 1 | ECTS2013 | Next issue

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

Card image cap
European Calcified Tissue Society Congress 2013, 18 - 22 May 2013; Lisbon, Portugal

Poster Presentations

Osteoporosis: treatment

Abstract unavailable
ba0001pp390
Electronic clinical decision support for the management of osteoporosis in primary care
Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
ba0001pp391
Anti-osteoporosis treatment amongst austrian hip fracture patients: status quo, and effects on mortality and subsequent fracture risk
1Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of the WGKK and AUVA Trauma Center, 1st Medical Department at Hanusch Hospital, Vienna, Austria; 2Sickness Fund Burgenland, Burgenländische Gebietskrankenkasse, Eisenstadt, Austria; 3Clinical Department of General Anesthesia and Intensive Care Medicine, Medical University of Vienna, Vienna, Austria.
ba0001pp392
Remarkable bone mineral density increases on teriparatide in patients with glucocorticoid-induced osteoporosis and Crohn's disease
1Porhealth Clinical Research, Vancouver, British Columbia, Canada; 2University of British Columbia, Vancouver, British Columbia, Canada; 3Eli Lily Canada Inc., Toronto, Ontario, Canada.
ba0001pp393
Effects of a new conjugate drug in a rat model of postmenopausal osteoporosis
1University of Toronto, Toronto, Canada; 2Simon Fraser University, Burnaby, Canada; 3Mount Sinai Hospital, Toronto, Canada.
ba0001pp394
Renal function and safety result after 1 year treatment of zoledronic acid in Chinese women with postmenopausal osteoporosis
1Department of Orthopaedics, the Second Affiliated Hospital of Sun Yat-Sen University, Guang Zhou, China; 2Beijing Novartis Pharma Co., Ltd., Beijing, China.
ba0001pp395
Intact heparin inhibits BMP6 osteogenic activity
Laboratory for Mineralized Tissues, School of Medicine, Center for Translational and Clinical Research, University of Zagreb, Zagreb, Croatia.
ba0001pp397
Health economic consequences of fractures in patients with osteoporosis: a national register based study of total and incremental health costs following fracture
1eMpirisk Aps, Frederiksberg, Denmark; 2Gentofte Hospital, Hellerup, Denmark; 3University of Southern Denmark, Odense, Denmark.
ba0001pp398
Assessment of serum 25-hydroxyvitamin D concentrations in postmenopausal osteoporotic women: a retrospective study to evaluate long-term treatment with vitamin D3
1Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark; 2Center for Clinical and Basic Research (CCBR), Aalborg, Denmark.
ba0001pp399
Osteonecrosis of the jaw and non-malignant disease
1Laboratory of Oral Molecular Physiopathology, INSERM, UMR 872, Cordeliers Research Center, Team 5, Universities Paris-Diderot, Paris 7, Pierre and Marie Curie and Paris-Descartes, Paris, France; 2Oral Surgery Department, Pitié-Salpêtrière University Hospital, Paris Diderot University, Paris, France; 3INSERM UMR-S 606, Hôpital Lariboisière, Ambroise Paré Street, Paris, France.
ba0001pp400
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis
1Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece; 2Ippokration Hospital,Second Medical Clinic, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Department of Medical Research, 251 Hellenic Air Force and VA General Hospital, Athens, Greece; 4Division of Nuclear Medicine, 251 Hellenic Air Force and VA General Hospital, Athens, Greece; 5Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece.
ba0001pp403
Sequential therapy after PTH 1[ndash]84 treatment: comparison among bisphosphonates and strontium ranelate
1UOC Endocrinologia, Ospedale S. Giovanni Calibita, Fatebenefratelli, Isola Tiberina, Rome, Italy; 2SeSMIT AFaR, Fatebenefratelli, Isola Tiberina, Rome, Italy.
ba0001pp404
Adherence to therapy: outcomes after seven years of treatment with bisphosphonates
UOC Endocrinology, Ospedale S. Giovanni Calibita, Fatebenefratelli, Isola Tiberina, Rome, Italy.
ba0001pp405
In real clinical practice osteoporosis drugs are taken for a very short period: analysis of persistence in the campania region
1Orthopaedics and Rehabilitation Medicine, Second University of Naples, Naples, Italy; 2CIRFF/Center of Pharmacoeconomics Faculty of Pharmacy University of Naples, ’FedericoII’, Naples, Italy.
ba0001pp406
Effect of a mixture of calcium, vitamin D, inulin and soy isoflavones on bone metabolism in post-menopausal women: a retrospective analysis
1Endocrinology and Diabetes Unit, Department of Medicine, Luigi Sacco Hospital (Vialba) – University of Milan, Milano, Italy; 2Medical Affairs, Medical Department, Bayer S.p.A. – Pharmaceuticals, Milano, Italy; 3IRCCS S. Maria Nascente, Rheumatology and Bone Metabolism Unit, Don Gnocchi Foundation ONLUS, Milano, Italy.
ba0001pp407
Vertebroplasty vs kyphoplasty in osteoporotic vertebral fractures: a finite element comparative analysis
1Dipartimento di Scienze della Salute, Università degli Studi, Milano, Italy; 2Laboratory of Biological Structure Mechanics, Department of Structural Engineering, Politecnico di Milano, Milano, Italy; 3IRCCS Istituto Ortopedico Galeazzi, Milano, Italy; 4UO Ortopedia, AO San Paolo, Milano, Italy.
ba0001pp408
Bone turnover markers and radiographic progression of vertebral compression fractures during anti-osteoporotic therapy
1Orthopaedic and Traumatologic Clinic, State University of Milan c/o AO Orthopaedic Institute G.Pini, Milan, Italy; 2Unit of Clinical Pathology, AO Orthopaedic Institute G.Pini, Milan, Italy.
ba0001pp410
Changes in low back pain and upper gastrointestinal symptoms in Japanese osteoporotic patients after switching to once-monthly oral minodronate from daily or weekly bisphosphonates
1Okimoto Clinic, Hiroshima, Japan; 2Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan; 3University of Occupational and Environmental Health, Fukuoka, Japan; 4Ken-Ai Memorial Hospital, Fukuoka, Japan; 5Saka Midorii Hospital, Hiroshima, Japan; 6Teshima Orthopaedic Clinic, Fukuoka, Japan; 7Sanzai Hospital, Miyazaki, Japan; 8Tsurukami Orthopaedic and Rheumatoid Clinic, Kumamoto, Japan; 9Makiyama Central Hospital, Fukuoka, Japan; 10Katsuki Neurosurgery and Orthopaedic Clinic, Fukuoka, Japan; 11Kitakyushu General Hospital, Fukuoka, Japan; 12Obase Hospital, Fukuoka, Japan.
ba0001pp411
Early response to once-monthly oral minodronate after switching from daily or weekly bisphosphonates in Japanese osteoporotic patients
1University of Occupational and Environmental Health, Kitakyushu, Japan; 2Ken-Ai Memorial Hospital, Onga, Japan; 3Okimoto Clinic, Kure, Japan; 4Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan; 5Teshima Orthopaedic Clinic, Kitakyushu, Japan; 6Obase Hospital, Kanda, Miyako, Japan; 7Sanzai Hospital, Saito, Japan; 8Tsurukami Orthopaedic and Rheumatoid Clinic, Tamana, Japan; 9Makiyama Central Hospital, Kitakyushu, Japan; 10Katsuki Neurosurgery and Orthopaedic Clinic, Nogata, Japan; 11Kitakyushu General Hospital, Kitakyushu, Japan; 12Saka Midorii Hospital, Hiroshima, Japan.
ba0001pp413
Patient preference and adherence to once-monthly oral minodronate in Japanese osteoporotic patients previously using daily or weekly bisphosphonates
1Ken-Ai Memorial Hospital, Onga, Fukuoka, Japan; 2University of Occupational and Environmental Health, Kitakyusyu, Fukuoka, Japan; 3Okimoto Clinic, Kure, Hiroshima, Japan; 4Teshima Orthopaedic Clinic, Kitakyusyu, Fukuoka, Japan; 5Obase Hospital, Miyako, Fukuoka, Japan; 6Sanzai Hospital, Miyazaki, Japan; 7Tsurukami Orthopaedic and Rheumatoid Clinic, Tamana, Fukuoka, Japan; 8Makiyama Central Hospital, Kitakyusyu, Fukuoka, Japan; 9Katsuki Neurosurgery and Orthopaedic Clinic, Nougata, Fukuoka, Japan; 10Kitakyushu General Hospital, Kitakyusyu, Fukuoka, Japan; 11Saka Midorii Hospital, Hiroshima, Japan; 12Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan.
ba0001pp415
Meta-analysis of the effects of vitamin D supplements on bone mineral density in adults
Department of Medicine, University of Auckland, Auckland, New Zealand.
ba0001pp416
A case of atypical femoral fracture with abnormal cortical bone characterized by impaired mineralization and pyrophosphate accumulation
1University of Oslo, Oslo, Norway; 2Oslo University Hospital, Oslo, Norway; 3Hanusch Hospital of WGKK, Vienna, Austria; 4Department of Internal Medicine, Barcelona, Spain.
ba0001pp417
Analysis of clinical assessment and efficacy of once-yearly i.v. zoledronic acid for osteoporosis
1Department of Orthopaedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, Kyunggi-do, Republic of Korea; 2Department of Orthopaedic Surgery, Ajou University Hospital College of Medicine, Suwon, Kyunggi-do, Republic of Korea; 3Department of Obstetrics and Gynecology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.
ba0001pp419
Subsequent hip fracture in Inchon and Bucheon area of Korea (Cohort study)
1School of Medicine, Inha University, Incheon, Republic of Korea; 2College of Medicine, The Catholic University of Korea, Bucheon, Republic of Korea.
ba0001pp420
The efficiency of bisphosphonates (alendronate, risedronate, ibandronate) for postmenopausal osteoporosis after 1 year of therapy
1C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
ba0001pp421
Bisphosphonates poisonous action
Moscow State University of Medicine and Dentistry, Moscow, Russia.
ba0001pp422
Acute phase response and zoledronic acid therapy
Research Center of Obstetrics, Gynecology and Perinatology, Moscow, Russia.
ba0001pp424
Evaluation with densitometry of patients with breast cancer and low bone mineral density after 2 years of treatment
1Hospital de Manises, Manises, Valencia, Spain; 2Hospital de La Ribera, Alzira, Valencia, Spain; 3Hospital Lluïs Alcanyis, Xàtiva, Valencia, Spain; 4Hospital General de Ontinyent, Ontinyent, Valencia, Spain.
ba0001pp425
Persistence with different anti-osteoporosis medications: a population-based cohort study.
1GREMPAL Research Group (USR Barcelona), IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain; 2URFOA, Institut Municipal d’Investigacions Mèdiques, Parc de Salut Mar-Universitat Autònoma de Barcelona, Barcelona, Spain; 3RETICEF (Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad), Instituto Carlos III, Barcelona, Spain; 4Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 5MRC Lifecourse Epidemiology Unit, Southampton, UK.
ba0001pp428
Study description and baseline characteristics of the population enrolled in the extended forsteo[reg] observational study (ExFOS)
1Aarhus university Hospital, Aarhus, Denmark; 2Hôpital d’Orléans La Source, Orléans La Source, France; 3Eli Lilly Sweden AB, Solna, Sweden; 4Levanger Hospital, Levanger, Norway; 5University Medical Centre Ljubljana, Ljubljana, Slovenia; 6University Hospital Uppsala, Uppsala, Sweden; 7University Campus Bio-Medico di Roma, Rome, Italy; 8Eli Lilly research centre, Vienna, Austria; 9Papageorgiou General Hospital, Thessaloniki, Greece; 10Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
ba0001pp429
Bisphosphonate treatment of painful vertebral fractures due to osteoporosis in five boys with Duchenne muscular dystrophy
1Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden; 2BM3, Karolinska University Hospital, Stockholm, Sweden.
ba0001pp431
Effects of a mutated sclerostin peptide on bone and lean mass in mice
1Division of Bone Diseases, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland; 2Lehrstuhl für Pflanzenphysiologie und Biophysik, Würzburg, Germany.
ba0001pp432
Denosumab is associated with progressive improvements in hip cortical mass and thickness
1University of Cambridge, Cambridge, UK; 2CHUQ-CHUL Research Centre, Quebec City, QC, Canada; 3Oregon Osteoporosis Center, Portland, OR, USA; 4Amgen Inc., Thousand Oaks, CA, USA.
ba0001pp433
Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension
1Laval University and CHUQ, Quebec City, QC, Canada; 2Amgen Inc., Thousand Oaks, CA, USA; 3Columbia University, New York, NY, USA; 4Helen Hayes Hospital, West Haverstraw, NY, USA; 5University of British Columbia, Vancouver, BC, Canada; 6Colorado Center for Bone Research, Lakewood, CO, USA; 7Bethesda Health Research Center, Bethesda, MD, USA; 8Center for Clinical and Basic Research, Tallinn, Estonia; 9Hvidovre Hospital, Hvidovre, Denmark; 10Hospital Heliopolis, Sao Paulo, Brazil; 11Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina; 12University of Auckland, Grafton, New Zealand.
ba0001pp434
Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study
1Paris Descartes University, Paris, France; 2Oregon Osteoporosis Center, Protland, Oregon, USA; 3Amgen, Inc., Thousand Oaks, California, USA; 4University of Verona, Verona, Italy; 5University of Melbourne, Melbourne, Victoria, Australia; 6University of Auckland, Auckland, New Zealand; 7St Vincent Hospital, University of Vienna, Vienna, Austria; 8Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre, France; 9University of Sheffield, Sheffield, UK.
ba0001pp435
Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials
1United Osteoporosis Centers, Gainesville, GA, USA; 2Paris Descartes University, Paris, France; 3Amgen Inc., Thousand Oaks, CA, USA; 4Michigan Bone and Mineral Clinic, Detroit, MI, USA; 5Clinical Research Center of North Texas, Denton, TX, USA; 6VieCuri Medical Centre, Maastricht University, Maastricht, The Netherlands; 7Amgen Ltd., Cambridge, UK; 8CHUQ-CHUL Research Centre, Quebec City, QC, Canada.
ba0001pp436
Optimizing fracture prevention: the fracture liaison service, an observational study
1VU University Medical Center, Amsterdam, The Netherlands; 2Isala Clinics, Zwolle, The Netherlands; 3Sint Franciscus Gasthuis, Rotterdam, The Netherlands; 4University Medical Center Utrecht, Utrecht, The Netherlands; 5University Hospital, Maastricht, The Netherlands; 6University Hasselt, Hasselt, Belgium.
ba0001pp438
Reducing the risk of hypocalcaemia with parenteral antiresorptive therapies: an audit
Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, UK.
ba0001pp441
Design of a prospective observational study to evaluate persistence and adherence during denosumab treatment, and patient characteristics in postmenopausal women with osteoporosis in routine clinical practice
1Amgen Ltd., Uxbridge, UK; 2Amgen Europe GmbH, Zug, Switzerland; 3Philipps University, Marburg, Germany; 4Amgen Ltd., Cambridge, UK; 5Amgen Inc., Thousand Oaks, California, USA; 6Leuven University, Leuven, Belgium; 7Medical University of Graz, Graz, Austria; 8University of Athens, Athens, Greece.
ba0001pp442
Zoledronic acid vs alendronate in the management of osteoporosis
1Department of Biochemistry, Glasgow Royal Infirmary, Glasgow, UK; 2Department of Bone Mineral Metabolism, Glasgow Royal Infirmary, Glasgow, UK.
ba0001pp443
Correction of vitamin D deficiency in women with postmenopausal osteoporosis
D.F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, Ukraine.
ba0001pp444
Effectiveness of the active metabolite of vitamin D in the treatment of postmenopausal osteoporosis
1M. Gorky Donetsky National Medical University, Donetsk, Ukraine; 2D.F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, Ukraine.
ba0001pp445
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate[ndash] a randomized placebo-controlled trial
1INSERM, Lyon, France, 2Mediclinic Panorama, Cape Town, South Africa, 3Clinical Research Center of North Texas, Denton, USA, 4Alta California Medical Group, Simi Valley, USA, 5Instituto Palacios, Madrid, Spain, 6Merck Sharp and Dohme, Whitehouse Station, USA.
ba0001pp446
Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use
1Hopital d’Orleans la Source, Orleans, France; 2Mediclinic Panorama, Western Cape, South Africa; 3Indiana University School of Medicine, Indianapolis, Indiana, USA; 4Aarhus University Hospital, Aarhus, Denmark; 5University of Alabama, Birmingham, Alabama, USA; 6Merck Sharp and Dohme Corp., Whitehouse Station, New Jersey, USA.
ba0001pp448
Odanacatib treatment reduces remodeling- and stimulates modeling-based bone formation in adult OVX monkeys
1Merck Sharp and Dohme Corp., Whitehouse Station, USA; 2PharmaLegacy Laboratory, Shanghai, China.
ba0001pp449
Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology
1University of Bern, Bern, Switzerland; 2Vienna University of Technology, Vienna, Austria; 3University of Erlangen, Erlangen, Germany; 4Synarc Germany, Hamburg, Germany; 5UCSF and Synarc, San Francisco, California, USA; 6Oregon Osteoporosis Center, Portland, Oregon, USA; 7University of British Columbia, Vancouver, British Columbia, Canada; 8United Osteoporosis Centers, Gainesville, Georgia, USA; 9University of Erlangen-Nuremberg, Erlangen-Nuremberg, Germany; 10Amgen Inc., Thousand Oaks, California, USA.
ba0001pp451
Factors influencing levels of bone resorption during denosumab dosing
1University of Sheffield, Sheffield, UK, 2Columbia University Medical Center, New York, NY, USA, 3Paris Descartes University, Paris, France, 4University of California, San Francisco, San Francisco, CA, USA, 5Amgen Inc., Thousand Oaks, CA, USA.
ba0001pp453